NCT06967519View on ClinicalTrials.gov

OPTImizing Malaria And HIV Treatment in a Shifting Landscape in Africa

PHASE4Not yet recruitingINTERVENTIONAL
Enrollment

380

Participants

Timeline

Start Date

September 30, 2025

Primary Completion Date

September 30, 2027

Study Completion Date

September 30, 2027

Conditions
MalariaHiv
Interventions
DRUG

Artemether-lumefantrine (AL)

Participants will receive the dispersible formulation of AL with contains 20 mg artemether, 120 mg of lumefantrine

DRUG

artesunate-amodiaquine (AS-AQ)

Children will receive the tablet formulations of Artesunate Amodiaquine using weight based dosing

Trial Locations (2)

Unknown

Baylor- Uganda, Kampala

Infectious Disease Research Collaboration (IDRC), Kampala

All Listed Sponsors
collaborator

Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

NIH

lead

Yale University

OTHER